The Citizens Life Sciences Conference 2026 March 10, 2026 4:00 PM EDTCompany ParticipantsMark Jacobson - Chief ...

Detailed price information for Mira Pharmaceuticals Inc (MIRA-Q) from The Globe and Mail including charting and trades.

The bipolar depression market is anticipated to increase during the forecast period (2026–2036), owing to the rise in the launch of emerging therapies ...

Some serious brain disorders begin with symptoms that are easy to misinterpret. A person may become confused, forgetful or paranoid and be treated for mental illness before doctors realize the ...

SHINKEI THERAPEUTICS RECEIVES FDA CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL FOR MR-101 AND COMPLETES PHASE 2 ...

Nearly 7 million Americans are living with Alzheimer’s, but researchers say millions more likely have symptoms but no formal ...

MIRA Pharmaceuticals has completed dosing in its Phase I clinical trial of Ketamir-2, the company’s selective oral N-methyl-D-aspartate (NMDA) receptor modulator, assessing its safety, tolerability, ...

Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following ...

For over thirty years, researchers have primarily studied the accumulation of amyloid beta proteins in the brains of Alzheimer’s patients. They also focus on how that component negatively impacts ...

The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of around 20% during the forecast period. This rapid expansion is primarily fueled by the rising prevalence of ...

While companies developing drugs to treat Alzheimer's disease have spent decades and many billions of dollars targeting ...

Scientists have zeroed in on a critical weak spot behind a rare but devastating brain autoimmune disorder often known as “Brain on Fire.” The disease strikes when the immune system attacks NMDA ...